Perspectives on new synthetic curcumin analogs and their potential anticancer properties

Current Pharmaceutical Design

Volumn 19, Issue 11, 2013, Pages 2047-2069

  Vyas, Alok ^a   Dandawate, Prasad ^a   Padhye, Subhash ^a,b   Ahmad, Aamir ^b   Sarkar, Fazlul ^b  

^a UNIVERSITY OF PUNE   (India)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anticancer; Curcumin; Curcumin analogs; Novel formulations

Indexed keywords

2 HYDROXYCURCUMINOID; 4 ETHOXYCARBONYLETHYLENYLCURCUMIN; 4 FLUORO 4 ETHOXYCARBONYLETHYLCURCUMIN; BENZOYLHYDRAZINOCURCUMIN; CETRIMIDE; CISPLATIN; CURCUMIN; CURCUMIN GLUCURONIDE; CURCUMIN SULFATE; DEXTRAN SULFATE; DI TETRAPYRANYLATED 4 ETHOXYCARBONYLETHYLENYLCURCUMIN; DIACETYLCURCUMIN; DIMETHOXYCURCUMIN; DODECYL SULFATE SODIUM; ETHOXY CURCUMIN TRI THIADIAZOL AMINO METHYLCARBONATE; ETHOXYCARBONYLETHYLCURCUMIN; HEXAHYDROCURCUMIN; HYDRAZINOCURCUMIN; ISOXAZOLE; LIPOSOME; NANOPARTICLE; PACLITAXEL; PHOSPHOLIPID; POLYSORBATE 80; PYRAZOLE; SALICYLCURCUMIN; TETRAHYDROCURCUMIN; TRITON X 100; UNCLASSIFIED DRUG; YAKUCHINONE A; YAKUCHINONE B;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; CANCER PREVENTION; CELL CYCLE ARREST; CELL DEATH; COMPLEX FORMATION; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EXCRETION; DRUG FORMULATION; DRUG METABOLISM; DRUG STABILITY; DRUG STRUCTURE; E22C; GLUCURONIDATION; HUMAN; METASTASIS; MICELLE; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR GROWTH;

EID: 84875397668     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811319110007     Document Type: Review

References (123)

1. Craig WJ. Health-promoting properties of common herbs. Am J Clin Nutr 1999; 70: 491S-9S.
2. Ammon HP, Safayhi H, Mack T, Sabieraj J. Mechanism of antiinflammatory actions of curcumine and boswellic acids. J Ethnopharmacol 1993; 38: 113-9.
3. Reddy AC, Lokesh BR. Studies on anti-inflammatory activity of spice principles and dietary n-3 polyunsaturated fatty acids on carrageenan- induced inflammation in rats. Ann Nutr Metab 1994; 38: 349-58.
4. Xu YX, Pindolia KR, Janakiraman N, et al. Curcumin, a compound with anti-inflammatory and anti-oxidant properties, down-regulates chemokine expression in bone marrow stromal cells. Exp Hematol 1997; 25: 413-22.
5. Banerjee M, Tripathi LM, Srivastava VM, Puri A, Shukla R. Modulation of inflammatory mediators by ibuprofen and curcumin treatment during chronic inflammation in rat. Immunopharmacol Immunotoxicol 2003; 25: 213-24.
6. Lantz RC, Chen GJ, Solyom AM, Jolad SD, Timmermann BN. The effect of turmeric extracts on inflammatory mediator production. Phytomedicine 2005; 12: 445-52.
7. Han SS, Chung ST, Robertson DA, Ranjan D, Bondada S. Curcumin causes the growth arrest and apoptosis of B cell lymphoma by downregulation of egr-1, c-myc, bcl-XL, NF-kappa B, and p53. Clin Immunol 1999; 93: 152-61.
8. Huang MT, Lou YR, Xie JG, et al. Effect of dietary curcumin and dibenzoylmethane on formation of 7,12-dimethylbenz[a] anthracene- induced mammary tumors and lymphomas/leukemias in Sencar mice. Carcinogenesis 1998; 19: 1697-700.
9. Jaiswal AS, Marlow BP, Gupta N, Narayan S. Beta-cateninmediated transactivation and cell-cell adhesion pathways are important in curcumin (diferuylmethane)-induced growth arrest and apoptosis in colon cancer cells. Oncogene 2002; 21: 8414-27.
10. Bhaumik S, Anjum R, Rangaraj N, Pardhasaradhi BV, Khar A. Curcumin mediated apoptosis in AK-5 tumor cells involves the production of reactive oxygen intermediates. FEBS Lett 1999; 456: 311-4.
11. Ranjan D, Chen C, Johnston TD, Jeon H, Nagabhushan M. Curcumin inhibits mitogen stimulated lymphocyte proliferation, NFkappaB activation, and IL-2 signaling. J Surg Res 2004; 121: 171-7.
12. Kunnumakkara AB, Anand P, Aggarwal BB. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett 2008; 269: 199-225.
13. Shishodia S, Singh T, Chaturvedi MM. Modulation of transcription factors by curcumin. Adv Exp Med Biol 2007; 595: 127-48.
14. Aggarwal S, Takada Y, Singh S, Myers JN, Aggarwal BB. Inhibition of growth and survival of human head and neck squamous cell carcinoma cells by curcumin via modulation of nuclear factorkappaB signaling. Int J Cancer 2004; 111: 679-92.
15. Choi H, Chun YS, Shin YJ, et al. Curcumin attenuates cytochrome P450 induction in response to 2,3,7,8-tetrachlorodibenzo-p-dioxin by ROS-dependently degrading AhR and ARNT. Cancer Sci 2008; 99: 2518-24.
16. Padhye S, Chavan D, Pandey S, et al. Perspectives on chemopreventive and therapeutic potential of curcumin analogs in medicinal chemistry. Mini Rev Med Chem 2010; 10: 372-87.
17. Milobedeska J, Kostanecki V, Lampe V. Structure of curcumin. Ber Dtsch Chem Ges 1910; 43: 2163-70.
18. Lampe V, Milobedeska J. Studien uber curcumin. Ber Dtsch Chem Ges 1913; 46: 2235-40.
19. Tonnesen HH, Karlsen J. Studies on curcumin and curcuminoids. VI. Kinetics of curcumin degradation in aqueous solution. Z Lebensm Unters Forsch 1985; 180: 402-4.
20. Wang YJ, Pan MH, Cheng AL, et al. Stability of curcumin in buffer solutions and characterization of its degradation products. J Pharm Biomed Anal 1997; 15: 1867-76.
21. Bernabe-Pineda M, Ramirez-Silva MT, Romero-Romo M, Gonzalez-Vergara E, Rojas-Hernandez A. Determination of acidity constants of curcumin in aqueous solution and apparent rate constant of its decomposition. Spectrochim Acta A Mol Biomol Spectrosc 2004; 60: 1091-7.
22. Ireson CR, Jones DJ, Orr S, et al. Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine. Cancer Epidemiol Biomarkers Prev 2002; 11: 105-11.
23. Holder GM, Plummer JL, Ryan AJ. The metabolism and excretion of curcumin (1,7-bis-(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene- 3,5-dione) in the rat. Xenobiotica 1978; 8: 761-8.
24. Padhye S, Banerjee S, Chavan D, et al. Fluorocurcumins as cyclooxygenase- 2 inhibitor: molecular docking, pharmacokinetics and tissue distribution in mice. Pharm Res 2009; 26: 2438-45.
25. Wang Z, Leung MH, Kee TW, English DS. The role of charge in the surfactant-assisted stabilization of the natural product curcumin. Langmuir 2010; 26: 5520-6.
26. Setthacheewakul S, Mahattanadul S, Phadoongsombut N, Pichayakorn W, Wiwattanapatapee R. Development and evaluation of selfmicroemulsifying liquid and pellet formulations of curcumin, and absorption studies in rats. Eur J Pharm Biopharm 2010; 76: 475-85.
27. Gao Y, Li Z, Sun M, et al. Preparation, characterization, pharmacokinetics, and tissue distribution of curcumin nanosuspension with TPGS as stabilizer. Drug Dev Ind Pharm 2010; 36: 1225-34.
28. Pandey MK, Kumar S, Thimmulappa RK, et al. Design, synthesis and evaluation of novel PEGylated curcumin analogs as potent Nrf2 activators in human bronchial epithelial cells. Eur J Pharm Sci 2011; 43: 16-24.
29. Tang H, Murphy CJ, Zhang B, et al. Curcumin polymers as anticancer conjugates. Biomaterials 2010; 31: 7139-49.
30. Ganta S, Devalapally H, Amiji M. Curcumin enhances oral bioavailability and anti-tumor therapeutic efficacy of paclitaxel upon administration in nanoemulsion formulation. J Pharm Sci 2010; 99: 4630-41.
31. Li L, Braiteh FS, Kurzrock R. Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. Cancer 2005; 104: 1322-31.
32. Anitha A, Deepagan VG, Divya Rani VV, et al. Preparation, characterization, in vitro drug release and biological studies of curcumin loaded dextran sulphate-chitosan nanoparticles. Carbohydrate Polymers 2011; 84: 1158-64.
33. HH. Studies on curcumin and curcuminoids. XVI. Effect of curcumin analogs on hyaluronic acid degradation in vitro. International Journal of Pharmaceutics 1989; 51: 259-61.
34. Tomren MA, Masson M, Loftsson T, Tonnesen HH. Studies on curcumin and curcuminoids: XXXI. Symmetric and asymmetric curcuminoids: Stability, activity and complexation with cyclodextrin. International Journal of Pharmaceutics 2007; 338: 27-34.
35. Yadav VR, Prasad S, Kannappan R, et al. Cyclodextrin-complexed curcumin exhibits anti-inflammatory and antiproliferative activities superior to those of curcumin through higher cellular uptake. Biochem Pharmacol 2010; 80: 1021-32.
36. Yallapu MM, Jaggi M, Chauhan SC. Poly(beta-cyclodextrin)/ curcumin self-assembly: a novel approach to improve curcumin delivery and its therapeutic efficacy in prostate cancer cells. Macromol Biosci 2010; 10: 1141-51.
37. Dandawate PR, Vyas A, Ahmad A, et al. Inclusion Complex of Novel Curcumin Analogue CDF and beta-Cyclodextrin (1: 2) and Its Enhanced In vivo Anticancer Activity Against Pancreatic Cancer. Pharm Res 2012.
38. Aggarwal S, Ndinguri MW, Solipuram R, et al. [DLys(6)]-luteinizing hormone releasing hormone-curcumin conjugate inhibits pancreatic cancer cell growth in vitro and in vivo. Int J Cancer 2011; 129: 1611-1623.
39. Al-Hujaily EM, Mohamed AG, Al-Sharif I, et al. PAC, a novel curcumin analogue, has anti-breast cancer properties with higher efficiency on ER-negative cells. Breast Cancer Res Treat 2011; 128: 97-107.
40. Al-Wabli R, AboulWafa O, Youssef KM. Synthesis of curcumin and ethylcurcumin bioconjugates as potential antitumor agents. Medicinal Chemistry Research 2012; 21: 874-890.
41. Devasena T, Rajasekaran KN, Menon VP. Bis-1,7-(2-hydroxyphenyl)- hepta-1,6-diene-3,5-dione (a curcumin analog) ameliorates DMH-induced hepatic oxidative stress during colon carcinogenesis. Pharmacol Res 2002; 46: 39-45.
42. Devasena T, Menon VP, Rajasekharan KN. Prevention of 1,2- dimethylhydrazine-induced circulatory oxidative stress by bis-1,7- (2-hydroxyphenyl)-hepta-1,6-diene-3,5-dione during colon carcinogenesis. Pharmacol Rep 2006; 58: 229-35.
43. Arafa HM. Possible contribution of beta-glycosidases and caspases in the cytotoxicity of novel glycoconjugates in colon cancer cells. Invest New Drugs 2010; 28: 306-17.
44. Dubey SK, Sharma AK, Narain U, Misra K, Pati U. Design, synthesis and characterization of some bioactive conjugates of curcumin with glycine, glutamic acid, valine and demethylenated piperic acid and study of their antimicrobial and antiproliferative properties. Eur J Med Chem 2008; 43: 1837-46.
45. Ferrari E, Lazzari S, Marverti G, et al. Synthesis, cytotoxic and combined cDDP activity of new stable curcumin derivatives. Bioorg Med Chem 2009; 17: 3043-52.
46. Fuchs JR, Pandit B, Bhasin D, et al. Structure-activity relationship studies of curcumin analogues. Bioorg Med Chem Lett 2009; 19: 2065-9.
47. Nakagawa-Goto K, Yamada K, Nakamura S, et al. Antitumor agents. 258. Syntheses and evaluation of dietary antioxidant-taxoid conjugates as novel cytotoxic agents. Bioorg Med Chem Lett 2007; 17: 5204-9.
48. Han YM, Shin DS, Lee YJ, et al. 2-Hydroxycurcuminoid induces apoptosis of human tumor cells through the reactive oxygen species-mitochondria pathway. Bioorg Med Chem Lett 2011; 21: 747- 751.
49. Handler N, Jaeger W, Puschacher H, Leisser K, Erker T. Synthesis of novel curcumin analogues and their evaluation as selective cyclooxygenase-1 (COX-1) inhibitors. Chem Pharm Bull (Tokyo) 2007; 55: 64-71.
50. Jankun J, Aleem AM, Malgorzewicz S, et al. Synthetic curcuminoids modulate the arachidonic acid metabolism of human platelet 12-lipoxygenase and reduce sprout formation of human endothelial cells. Mol Cancer Ther 2006; 5: 1371-82.
51. Kapoor N, Sharma AK, Dwivedi V, et al. Telomerase targeted anticancer bioactive prodrug by antisense-based approach. Cancer Lett 2007; 248: 245-50.
52. Khan MA, El-Khatib R, Rainsford KD, Whitehouse MW. Synthesis and anti-inflammatory properties of some aromatic and heterocyclic aromatic curcuminoids. Bioorg Chem 2012; 40: 30-8.
53. Li J, Wang Y, Yang C, et al. Polyethylene glycosylated curcumin conjugate inhibits pancreatic cancer cell growth through inactivation of Jab1. Mol Pharmacol 2009; 76: 81-90.
54. Manju S, Sreenivasan K. Synthesis and characterization of a cytotoxic cationic polyvinylpyrrolidone-curcumin conjugate. J Pharm Sci 2011; 100: 504-11.
55. Mishra S, Kapoor N, Mubarak AA, et al. Differential apoptotic and redox regulatory activities of curcumin and its derivatives. Free Radic Biol Med 2005; 38: 1353-60.
56. Qiu X, Liu Z, Shao WY, et al. Synthesis and evaluation of curcumin analogues as potential thioredoxin reductase inhibitors. Bioorg Med Chem 2008; 16: 8035-41.
57. Safavy A, Raisch KP, Mantena S, et al. Design and development of water-soluble curcumin conjugates as potential anticancer agents. J Med Chem 2007; 50: 6284-8.
58. Tamvakopoulos C, Dimas K, Sofianos ZD, et al. Metabolism and anticancer activity of the curcumin analogue, dimethoxycurcumin. Clin Cancer Res 2007; 13: 1269-77.
59. Wichitnithad W, Nimmannit U, Wacharasindhu S, Rojsitthisak P. Synthesis, characterization and biological evaluation of succinate prodrugs of curcuminoids for colon cancer treatment. Molecules 2011; 16: 1888-900.
60. Youssef D, Nichols CE, Cameron TS, et al. Design, synthesis, and cytostatic activity of novel cyclic curcumin analogues. Bioorg Med Chem Lett 2007; 17: 5624-9.
61. Vyas HK, Pal R, Vishwakarma R, Lohiya NK, Talwar GP. Selective killing of leukemia and lymphoma cells ectopically expressing hCGbeta by a conjugate of curcumin with an antibody against hCGbeta subunit. Oncology 2009; 76: 101-11.
62. Yodkeeree S, Ampasavate C, Sung B, Aggarwal BB, Limtrakul P. Demethoxycurcumin suppresses migration and invasion of MDAMB-231 human breast cancer cell line. Eur J Pharmacol 2010; 627: 8-15.
63. Ryu MJ, Cho M, Song JY, et al. Natural derivatives of curcumin attenuate the Wnt/beta-catenin pathway through down-regulation of the transcriptional coactivator p300. Biochem Biophys Res Commun 2008; 377: 1304-8.
64. Das J, Pany S, Panchal S, Majhi A, Rahman GM. Binding of isoxazole and pyrazole derivatives of curcumin with the activator binding domain of novel protein kinase C. Bioorg Med Chem 2011; 19: 6196-202.
65. Labbozzetta M, Baruchello R, Marchetti P, et al. Lack of nucleophilic addition in the isoxazole and pyrazole diketone modified analogs of curcumin; implications for their antitumor and chemosensitizing activities. Chem Biol Interact 2009; 181: 29-36.
66. Poma P, Notarbartolo M, Labbozzetta M, et al. The antitumor activities of curcumin and of its isoxazole analogue are not affected by multiple gene expression changes in an MDR model of the MCF-7 breast cancer cell line: analysis of the possible molecular basis. Int J Mol Med 2007; 20: 329-35.
67. Sahoo BK, Ghosh KS, Dasgupta S. Molecular interactions of isoxazolcurcumin with human serum albumin: spectroscopic and molecular modeling studies. Biopolymers 2009; 91: 108-19.
68. Dutta S, Padhye S, Priyadarsini KI, Newton C. Antioxidant and antiproliferative activity of curcumin semicarbazone. Bioorg Med Chem Lett 2005; 15: 2738-44.
69. Lal J, Gupta SK, Thavaselvam D, Agarwal DD. Design, synthesis, synergistic antimicrobial activity and cytotoxicity of 4-aryl substituted 3,4-dihydropyrimidinones of curcumin. Bioorg Med Chem Lett 2012; 22: 2872-6.
70. Shim JS, Kim DH, Jung HJ, et al. Hydrazinocurcumin, a novel synthetic curcumin derivative, is a potent inhibitor of endothelial cell proliferation. Bioorg Med Chem 2002; 10: 2987-92.
71. Shim JS, Lee J, Park HJ, Park SJ, Kwon HJ. A new curcumin derivative, HBC, interferes with the cell cycle progression of colon cancer cells via antagonization of the Ca2+/calmodulin function. Chem Biol 2004; 11: 1455-63.
72. Simoni D, Rizzi M, Rondanin R, et al. Antitumor effects of curcumin and structurally beta-diketone modified analogs on multidrug resistant cancer cells. Bioorg Med Chem Lett 2008; 18: 845-9.
73. Swarts SG, Zhang M, Yin L, et al. Antioxidant properties of select radiation mitigators based on semicarbazone and pyrazole derivatives of curcumin. Adv Exp Med Biol 2011; 701: 291-7.
74. Arif M, Vedamurthy BM, Choudhari R, et al. Nitric oxidemediated histone hyperacetylation in oral cancer: target for a watersoluble HAT inhibitor, CTK7A. Chem Biol 2010; 17: 903-13.
75. Chun KS, Sohn Y, Kim HS, et al. Anti-tumor promoting potential of naturally occurring diarylheptanoids structurally related to curcumin. Mutat Res 1999; 428: 49-57.
76. Wu JC, Lai CS, Badmaev V, et al. Tetrahydrocurcumin, a major metabolite of curcumin, induced autophagic cell death through coordinative modulation of PI3K/Akt-mTOR and MAPK signaling pathways in human leukemia HL-60 cells. Mol Nutr Food Res 2011; 55: 1646-54.
77. Yodkeeree S, Garbisa S, Limtrakul P. Tetrahydrocurcumin inhibits HT1080 cell migration and invasion via downregulation of MMPs and uPA. Acta Pharmacol Sin 2008; 29: 853-60.
78. Yoysungnoen P, Wirachwong P, Changtam C, Suksamrarn A, Patumraj S. Anti-cancer and anti-angiogenic effects of curcumin and tetrahydrocurcumin on implanted hepatocellular carcinoma in nude mice. World J Gastroenterol 2008; 14: 2003-9.
79. Chen CY, Yang WL, Kuo SY. Cytotoxic activity and cell cycle analysis of hexahydrocurcumin on SW 480 human colorectal cancer cells. Nat Prod Commun 2011; 6: 1671-2.
80. Ohtsu H, Xiao Z, Ishida J, et al. Antitumor agents. 217. Curcumin analogues as novel androgen receptor antagonists with potential as anti-prostate cancer agents. J Med Chem 2002; 45: 5037-42.
81. Lin L, Shi Q, Su CY, Shih CC, Lee KH. Antitumor agents 247. New 4-ethoxycarbonylethyl curcumin analogs as potential antiandrogenic agents. Bioorg Med Chem 2006; 14: 2527-34.
82. Lin L, Shi Q, Nyarko AK, et al. Antitumor agents. 250. Design and synthesis of new curcumin analogues as potential anti-prostate cancer agents. J Med Chem 2006; 49: 3963-72.
83. Amolins MW, Peterson LB, Blagg BS. Synthesis and evaluation of electron-rich curcumin analogues. Bioorg Med Chem 2009; 17: 360-7.
84. Arezki A, Chabot GG, Quentin L, et al. Synthesis and biological evaluation of novel ferrocenyl curcuminoid derivatives. Med Chem Commun 2011; 2: 190-5.
85. Lin L, Hutzen B, Zuo M, et al. Novel STAT3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreatic and breast cancer cells. Cancer Res 2010; 70: 2445-54.
86. Lin L, Fuchs J, Li C, et al. STAT3 signaling pathway is necessary for cell survival and tumorsphere forming capacity in ALDH/CD133 stem cell-like human colon cancer cells. Biochem Biophys Res Commun 2011; 416: 246-51.
87. Bill MA, Fuchs JR, Li C, et al. The small molecule curcumin analog FLLL32 induces apoptosis in melanoma cells via STAT3 inhibition and retains the cellular response to cytokines with anti-tumor activity. Mol Cancer 2010; 9: 165.
88. Chakraborti S, Das L, Kapoor N, et al. Curcumin recognizes a unique binding site of tubulin. J Med Chem 2011; 54: 6183-96.
89. Chen C, Liu Y, Chen Y, Xu J. C086, a novel analog of curcumin, induces growth inhibition and down-regulation of NFkappaB in colon cancer cells and xenograft tumors. Cancer Biol Ther 2011; 12: 797-807.
90. Fadda A, Badria F, El-Attar K. Synthesis and evaluation of curcumin analogues as cytotoxic agents. Medicinal Chemistry Research 2010; 19: 413-30.
91. Ferrari E, Pignedoli F, Imbriano C, et al. Newly synthesized curcumin derivatives: crosstalk between chemico-physical properties and biological activity. J Med Chem 2011; 54: 8066-77.
92. Qiu X, Du Y, Lou B, et al. Synthesis and Identification of New 4-Arylidene Curcumin Analogues as Potential Anticancer Agents Targeting Nuclear Factor-kappaB Signaling Pathway. J Med Chem 2010.
93. Sertel S, Eichhorn T, Bauer J, et al. Pharmacogenomic determination of genes associated with sensitivity or resistance of tumor cells to curcumin and curcumin derivatives. J Nutr Biochem 2011.
94. Zhou J, Geng G, Shi Q, Sauriol F, Wu JH. Design and synthesis of androgen receptor antagonists with bulky side chains for overcoming antiandrogen resistance. J Med Chem 2009; 52: 5546-50.
95. Zambre AP, Kulkarni VM, Padhye S, Sandur SK, Aggarwal BB. Novel curcumin analogs targeting TNF-induced NF-kappaB activation and proliferation in human leukemic KBM-5 cells. Bioorg Med Chem 2006; 14: 7196-204.
96. Padhye S, Yang H, Jamadar A, et al. New difluoro Knoevenagel condensates of curcumin, their Schiff bases and copper complexes as proteasome inhibitors and apoptosis inducers in cancer cells. Pharm Res 2009; 26: 1874-80.
97. Ali S, Ahmad A, Banerjee S, et al. Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF. Cancer Res 2010; 70: 3606-17.
98. Bao B, Ali S, Kong D, et al. Anti-tumor activity of a novel compound- CDF is mediated by regulating miR-21, miR-200, and PTEN in pancreatic cancer. PLoS One 2011; 6: e17850.
99. Kanwar SS, Yu Y, Nautiyal J, et al. Difluorinated-curcumin (CDF): a novel curcumin analog is a potent inhibitor of colon cancer stem-like cells. Pharm Res 2011; 28: 827-38.
100. Ali S, Ahmad A, Aboukameel A, et al. Increased Ras GTPase activity is regulated by miRNAs that can be attenuated by CDF treatment in pancreatic cancer cells. Cancer Lett 2012; 319: 173- 181.
101. Li Y, Kong D, Wang Z, et al. Inactivation of AR/TMPRSS2-ERG/Wnt signaling networks attenuates the aggressive behavior of prostate cancer cells. Cancer Prev Res (Phila) 2011; 4: 1495-506.
102. Bertini I, Gray HB, Lippard SJ, Valentine JS. Bioinorganic chemistry. New Delhi: Viva Books Pvt Ltd; 1998.
103. Gielen M, Tiekink E. Metallotherapeutic drugs and metal-based diagnostic agents: the use of metals in medicine. Wiley Publications; 2005.
104. Jiao Y, Wilkinson J, Di X, et al. Curcumin, a cancer chemopreventive and chemotherapeutic agent, is a biologically active iron chelator. Blood 2009; 113: 462-9.
105. Aliaga-Alcalde N, Marques-Gallego P, Kraaijkamp M, et al. Copper curcuminoids containing anthracene groups: fluorescent molecules with cytotoxic activity. Inorg Chem 2010; 49: 9655-63.
106. Annaraj J, Srinivasan S, Ponvel KM, Athappan P. Mixed ligand copper(II) complexes of phenanthroline/bipyridyl and curcumin diketimines as DNA intercalators and their electrochemical behavior under Nafion and clay modified electrodes. J Inorg Biochem 2005; 99: 669-76.
107. Barik A, Mishra B, Shen L, et al. Evaluation of a new copper(II)-curcumin complex as superoxide dismutase mimic and its free radical reactions. Free Radic Biol Med 2005; 39: 811-22.
108. Caruso F, Rossi M, Benson A, et al. Ruthenium-arene complexes of curcumin: X-ray and density functional theory structure, synthesis, and spectroscopic characterization, in vitro antitumor activity, and DNA docking studies of (p-cymene)Ru(curcuminato)chloro. J Med Chem 2012; 55: 1072-81.
109. John VD, Krishnankutty K. Antitumour activity of synthetic curcuminoid analogues (1,7-diaryl-1,6-heptadiene-3,5-diones) and their copper complexes. Appl Organometal Chem 2006; 20: 477- 482.
110. Valentini A, Conforti F, Crispini A, et al. Synthesis, oxidant properties, and antitumoral effects of a heteroleptic palladium(II) complex of curcumin on human prostate cancer cells. J Med Chem 2009; 52: 484-91.
111. Ruan BF, Lu X, Li TT, et al. Synthesis, biological evaluation and molecular docking studies of resveratrol derivatives possessing curcumin moiety as potent antitubulin agents. Bioorg Med Chem 2012; 20: 1113-21.
112. Cao B, Wang Y, Ding K, Neamati N, Long YQ. Synthesis of the pyridinyl analogues of dibenzylideneacetone (pyr-dba) via an improved Claisen-Schmidt condensation, displaying diverse biological activities as curcumin analogues. Org Biomol Chem 2012; 10: 1239-45.
113. Somers-Edgar TJ, Taurin S, Larsen L, et al. Mechanisms for the activity of heterocyclic cyclohexanone curcumin derivatives in estrogen receptor negative human breast cancer cell lines. Invest New Drugs 2011; 29: 87-97.
114. Kudo C, Yamakoshi H, Sato A, et al. Synthesis of 86 species of 1,5-diaryl-3-oxo-1,4-pentadienes analogs of curcumin can yield a good lead in vivo. BMC Pharmacol 2011; 11: 4.
115. Kalai T, Kuppusamy ML, Balog M, et al. Synthesis of Nsubstituted 3,5-bis(arylidene)-4-piperidones with high antitumor and antioxidant activity. J Med Chem 2011; 54: 5414-21.
116. Karthikeyan NS, Sathiyanarayanan KI, Aravindan PG, Giridharan P. Synthesis, crystal structure, and anticancer properties of cyclic monocarbonyl analogs of curcumin. Medicinal Chemistry Research 2011; 20: 81-7.
117. Dayton A, Selvendiran K, Kuppusamy ML, et al. Cellular uptake, retention and bioabsorption of HO-3867, a fluorinated curcumin analog with potential antitumor properties. Cancer Biol Ther 2010; 10: 1027-32.
118. Lin L, Hutzen B, Ball S, et al. New curcumin analogues exhibit enhanced growth-suppressive activity and inhibit AKT and signal transducer and activator of transcription 3 phosphorylation in breast and prostate cancer cells. Cancer Sci 2009; 100: 1719-27.
119. Yamakoshi H, Ohori H, Kudo C, et al. Structure-activity relationship of C5-curcuminoids and synthesis of their molecular probes thereof. Bioorg Med Chem 2010; 18: 1083-92.
120. Liang G, Shao L, Wang Y, et al. Exploration and synthesis of curcumin analogues with improved structural stability both in vitro and in vivo as cytotoxic agents. Bioorg Med Chem 2009; 17: 2623- 2631.
121. Ohori H, Yamakoshi H, Tomizawa M, et al. Synthesis and biological analysis of new curcumin analogues bearing an enhanced potential for the medicinal treatment of cancer. Mol Cancer Ther 2006; 5: 2563-71.
122. Ravindran J, Subbaraju GV, Ramani MV, Sung B, Aggarwal BB. Bisdemethylcurcumin and structurally related hispolon analogues of curcumin exhibit enhanced prooxidant, anti-proliferative and anti-inflammatory activities in vitro. Biochem Pharmacol 2010; 79: 1658-66.
123. Youssef KM, El-Sherbeny MA. Synthesis and antitumor activity of some curcumin analogs. Arch Pharm (Weinheim) 2005; 338: 181-189.